Uses of 'good laboratory practices' by regulated industry and agencies, and the safety of bisphenol A

Journal of Epidemiology and Community Health

Volumn 65, Issue 6, 2011, Pages 475-476

  Tweedale, Anthony C ^a  

^a RISK Consultancy   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; PHENOL DERIVATIVE;

DRUG INDUSTRY; DRUG TOXICITY; GOVERNMENT REGULATION; HUMAN; NOTE; UNITED STATES;

DRUG INDUSTRY; DRUG TOXICITY; GOVERNMENT REGULATION; HUMANS; PHENOLS; UNITED STATES;

EID: 79956200132     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech.2010.127761     Document Type: Note

References (14)

1. European Food Safety Authority. EFSA updates advice on bisphenol A. http://www.efsa.europa.eu/en/press/news/cef100930.htm (accessed Nov 2010).
2. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research. JAMA 2003;289:454-65.
3. Fagin D, Lavelle M. Center for Public Integrity. Toxic Deception: How the Chemical Industry Manipulates Science, Bends the Law and Endangers Your Health. 2nd Edition. Monroe, ME: Common Courage Press, 1999:190.
4. Swaen GM, Meijers JM. Influence of design characteristics on the outcome of retrospective cohort studies. Br J Ind Med 1988;45:624-9.
5. vom Saal FS, Hughes C. An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. Environ Health Perspect 2005;113:926-33.
6. Baldeshwiler AM. History of FDA good laboratory practices. Quality Assurance Journal 2003;7:157-61.
7. Organization for Economic Co-Operation & Development. Good Laboratory PracticedOECD Principles and Guidance for Compliance Monitoring. Paris, France: OECD Publishing, 2010:140.
8. Klimisch HJ, Andreae M, Tillmann U. A systematic approach for evaluating the quality of experimental toxicological and ecotoxicological data. Regul Toxicol Pharmacol 1997;1:1-5.
9. Klaasen C, ed. Casarett & Doull's Toxicology: The Basic Science of Poisons. 7th Edition. New York City: McGraw Hill, 2007:1280.
10. Ray LB, Gough NR. Orienteering strategies for a signaling maze. Science 2002;296:632-3.
11. Welshons WV, Thayer KA, Judy BM, et al. Large effects from small exposures. I. Mechanisms for endocrine disrupting chemicals with estrogenic activity. Environ Health Perspect 2003;111:994-1006.
12. Sheehan DM. No-threshold doseeresponse curves for nongenotoxic chemicals: findings and applications for risk assessment. Environ Res 2006;100:93-9.
13. Vandenberg LN, Chahoud I, Padmanabhan V, et al. Biomonitoring studies should be used by regulatory agencies to assess human exposure levels and safety of bisphenol A. Environ Health Perspect 2010;118:1051-4.
14. Myers JP, vom Saal FS, Akingbemi BT, et al. Why public health agencies cannot depend on good laboratory practices as a criterion for selecting data: the case of bisphenol A. Environ Health Perspect 2009;117:309-15.